Benefits
Abdominal discomfort, bloating and stool form
In adults diagnosed with IBS, strain Unique IS2 (2 billion CFU daily for 8 weeks) eased abdominal pain and increased complete bowel movements versus placebo, and strain MTCC 5856 improved bloating, pain and stool frequency in a small pilot in diarrhea-type IBS. A strain-by-strain meta-analysis supported Unique IS2 but pooled only two trials, one of them in children; each strain's trials were run by its maker.
After-meal gas and abdominal discomfort in adults without a diagnosis
In 61 adults with after-meal gas but no digestive diagnosis, a product with strain GBI-30, 6086 improved abdominal pain and total gut-symptom scores more than placebo over 4 weeks. Bloating showed only a trend, and a strong placebo response meant many other measures did not differ between groups. This is a single small trial.
Stool frequency and consistency
Strain Unique IS2 increased bowel movements in 100 adults with functional constipation and reduced hard stools in 144 healthy adults with infrequent bowel movements, without changing overall gut symptoms in the second trial. Strain GBI-30, 6086 raised weekly stools in 111 healthy adults. A meta-analysis of pooled Unique IS2 trials, however, found no significant rise in stool frequency.
Studied as an add-on to oral rehydration in children
In 110 children aged 1 to 10 with acute diarrhea, strain MTCC 5856 given with oral rehydration and zinc for 5 days shortened diarrhea by about 11 hours versus placebo, though daily stool frequency did not differ. An earlier trial in 148 children aged 6 to 24 months using an unnamed strain found no effect. Diarrhea in young children needs medical care.
Amino acid absorption from protein
Taken with a daily protein shake, strain GBI-30, 6086 raised blood amino acid levels after the meal in two small crossover studies of 30 people each (milk protein, and rice and pea protein). Strain Unique IS2 taken with whey for 60 days raised blood amino acids in trained men, and the authors also report gains in leg-press strength. Apart from that strength result, these are blood markers from small, maker-linked studies.
Mechanism of action
Spores that pass the stomach and germinate in the gut
Bacillus coagulans forms tough spores. Maker-linked research on strain GBI-30, 6086 describes the spores surviving stomach acid and germinating in the intestine, where the bacteria become active. How many spores of a given product survive and germinate in people has rarely been measured directly, and it can differ by strain and formulation.
Lactic acid production
Once active, the bacterium ferments sugars into lactic acid. A lower local pH is a proposed way it shifts the gut environment. Trials have measured only small changes in gut bacteria, and one trial found no change in microbiota composition at all.
Help with breaking down dietary protein
Strain GBI-30, 6086 increased protein digestion in a laboratory model of the stomach and small intestine. The proposed idea is that germinated cells release protein-digesting enzymes that free more amino acids for absorption. Higher blood amino acid levels after a protein meal fit this idea, but the enzyme effect itself has not been measured in people.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU daily for 8 weeks, after a 2-week placebo run-in (Madempudi et al. 2019, Sci Rep).
136 adults aged 18 to 60 meeting Rome III criteria for IBS, randomized after a run-in that excluded non-compliant participants.
Both primary outcomes, abdominal pain intensity and complete spontaneous bowel movements, improved more than with placebo, as did secondary symptoms. Blood inflammatory markers did not change. No severe adverse events were reported. Three authors are employees of the strain's maker.
Randomized, double-blind, placebo-controlled, three-center pilot of Bacillus coagulans strain MTCC 5856, 2 billion CFU/day for 90 days on top of standard care (Majeed et al. 2016, Nutr J).
36 people newly diagnosed with diarrhea-predominant IBS (18 per group).
Bloating, vomiting, diarrhea, abdominal pain and stool frequency improved more than with placebo (p < 0.01), and quality of life rose. The trial was small and was run by the strain's maker, Sami Labs and Sabinsa.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU/day for 4 weeks after a 2-week run-in (LeMoire et al. 2025, Benef Microbes).
144 healthy adults averaging 3 to fewer than 7 complete bowel movements per week.
Bowel movement frequency, the primary outcome, rose significantly (p = 0.037), and stool consistency improved more than with placebo (p = 0.018), mainly through fewer hard stools. There was no effect on GI symptoms, quality of life or gut microbiota. PepsiCo sponsored the trial, and three co-authors work there.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain GBI-30, 6086, 1 billion per day for 4 weeks (Gang et al. 2025, Benef Microbes).
111 healthy adults aged 18 to 65 with functional GI complaints that did not meet criteria for a disease.
Stools per week increased (p = 0.036), consistency improved (p < 0.001) and fewer participants had constipation versus placebo. Gut bacteria changed only slightly. Several authors work for Kerry, which sells the strain.
Randomized, double-blind, placebo-controlled trial of strain MTCC 5856 (400 million spores) or placebo with oral rehydration solution and zinc for 5 days (Majeed et al. 2023, Front Pediatr).
110 non-hospitalized children aged 1 to 10 with acute diarrhea of any cause.
Diarrhea lasted 51.3 hours with the probiotic versus 62.7 hours with placebo (p = 0.011), and dehydration status improved more. Daily diarrhea frequency was lower but not significantly. Most authors are employees of the maker.
Randomized, double-blind, placebo-controlled hospital trial of Lactobacillus sporogenes (Bacillus coagulans) tablets of unstated strain, given with oral rehydration (Dutta et al. 2011, Trop Med Int Health).
148 children aged 6 to 24 months with acute watery diarrhea and some dehydration (78 probiotic, 70 placebo).
Recovery rate, duration, frequency and volume of diarrhea, and rehydration fluid intake did not differ significantly between groups, including in rotavirus cases. The authors concluded the product had no therapeutic impact. This null result is one reason findings for one strain should not be assumed for another.
Randomized, double-blind crossover with two 14-day supplementation periods separated by a 3-week washout: 20 g rice and pea protein daily with or without 1 billion CFU BC30, with blood sampling for 4 hours after the final dose (Walden et al. 2024, Probiotics Antimicrob Proteins).
30 healthy women, average age 58.5.
Total amino acids, essential amino acids, tryptophan, cysteine and alanine had greater area under the curve with BC30 (p values 0.003 to 0.050). Time to peak was similar. Blood amino acids are a marker, not a muscle or health outcome. Funded by Kerry.
Double-blind, placebo-controlled trial: 20 g whey protein daily with 2 billion CFU Unique IS-2 or with placebo for 60 days alongside a controlled resistance-training program (Tarik et al. 2022, Eur J Nutr).
Resistance-trained men averaging 21 years old.
Total plasma free amino acids rose 16.1% (p = 0.004), and branched-chain amino acids were 33.1% higher than with placebo at 60 days. The authors also report a probiotic effect on leg-press 1RM (+16.6%, p = 0.024) and vertical jump power (+7.9%, p = 0.007). One trial, with two co-authors from the strain's maker.